Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Guidelines from the European Society for Blood and Marrow Transplantation (EBMT) on the Use of Defibrotide to Prevent Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in High-Risk Pediatric Patients

  • By

  • Selim Corbacioglu

  • Rajinder Bajwa

  • Ali Bülent Antmen

  • Adriana Balduzzi

  • Jaap Jan Boelens

  • Francesca Bonifazi

  • Simone Cesaro

  • Fabio Ciceri

  • Antonio Colecchia

  • Fiona Dignan

  • Katharina Kleinschmidt

  • Kris M. Mahadeo

  • Antonio Pagliuca

  • Petr Sedlacek

  • Peter J. Shaw

  • Jerry Stein

  • Zofia Szmit

  • Francesco Tambaro

  • Elif Ince

  • Marta Verna

  • Akif Yesilipek

  • Marco Zecca

  • Paul G. Richardson

  • Mohamad Mohty

  • Krzysztof Kalwak

  • January 13, 2026

Share

  • 1

    Sinusoidal Obstruction Syndrome (SOS/VOD) is a severe post-transplant complication in children, with incidence rates exceeding 15%.

  • 2

    Anicteric SOS/VOD occurs in up to 30% of pediatric patients, complicating diagnosis due to the lack of hyperbilirubinemia.

  • 3

    The European Society for Blood and Marrow Transplantation established pediatric-specific diagnostic criteria to improve SOS/VOD detection.

  • 4

    Defibrotide has shown promise in reducing endothelial damage and improving outcomes in pediatric patients at risk for SOS/VOD.

  • 5

    Diagnostic criteria significantly influence the reported incidence and severity of SOS/VOD, with the pEBMT criteria being more sensitive than previous standards.

Original Source(s)

Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)

  • by Selim Corbacioglu, Rajinder Bajwa, Ali Bülent Antmen, Adriana Balduzzi, Jaap Jan Boelens, Francesca Bonifazi, Simone Cesaro, Fabio Ciceri, Antonio Colecchia, Fiona Dignan, Katharina Kleinschmidt, Kris M. Mahadeo, Antonio Pagliuca, Petr Sedlacek, Peter J. Shaw, Jerry Stein, Zofia Szmit, Francesco Tambaro, Elif Ince, Marta Verna, Akif Yesilipek, Marco Zecca, Paul G. Richardson, Mohamad Mohty, Krzysztof Kalwak

  • January 13, 2026

Related Content

Investigation of Risk Factors Linked to Bloodstream Infections from Candida parapsilosis in Children and Factors Influencing Fluconazole Resistance: A 15-Year Retrospective Cohort Study

Combined JAK- and TNFα-targeting in severe steroid-refractory graft-versus-host disease in children

Physicians’ attitudes and perceptions toward the integration of artificial intelligence into pediatric hematology–oncology in Saudi Arabia